Studies Show Increased Risk of Heart Rhythm Problems with Seizure and Mental Health Medicine Lamotrigine (Lamictal) in Patients with Heart Disease

Why It Matters

The alert forces clinicians to reassess lamotrigine use in cardiac patients, potentially altering prescribing practices and prompting heightened monitoring for a widely used neurologic and psychiatric drug.

Key Takeaways

• FDA flags lamotrigine arrhythmia risk for heart disease patients
• In vitro studies ordered after ECG abnormalities and cardiac events
• Risk heightened with structural heart disorders or sodium‑channel blockers
• Patients urged not to discontinue without medical guidance
• Reporting side effects to MedWatch encouraged for lamotrigine

Pulse Analysis

The FDA’s latest safety communication on lamotrigine (Lamictal) underscores a growing regulatory focus on cardiac safety for neurologic and psychiatric drugs. While lamotrigine has been a mainstay for seizures and bipolar disorder for more than a quarter‑century, recent in‑vitro data suggest it can prolong cardiac repolarization and trigger arrhythmias in patients with pre‑existing heart disease. This move follows a series of earlier alerts—from immune reactions to teratogenic concerns—demonstrating the agency’s willingness to revisit older products when new mechanistic evidence emerges.

For clinicians, the warning translates into a nuanced risk‑benefit assessment. Patients with structural heart conditions such as heart failure, valvular disease, or channelopathies now require baseline ECG evaluation before initiating or continuing lamotrigine. The risk may be amplified when the drug is combined with other sodium‑channel blockers, a common scenario in polypharmacy for epilepsy or mood disorders. Discontinuation without medical supervision remains discouraged, as abrupt withdrawal can precipitate seizures or mood destabilization, highlighting the need for gradual tapering under specialist oversight.

The broader implication is a push toward more proactive pharmacovigilance. By mandating post‑market in‑vitro cardiac studies, the FDA signals that safety signals, even those derived from laboratory models, can trigger label updates and guide clinical practice. Healthcare providers are also urged to report adverse events through MedWatch, enriching the data pool that may prompt further investigations or class‑wide evaluations of sodium‑channel blockers. As the therapeutic landscape evolves, stakeholders must balance innovative treatment options with vigilant monitoring to protect patients with comorbid cardiovascular disease.